TipRanks - 2025-02-14 15:43
LIXTE Biotechnology (LIXT) announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 434,784 shares of the company’s common stock at a purchase price of $2.415 per share. In addition, in a concurrent private placement, the company issued unregistered warrants to purchase up to an aggregate of 434,784 shares of common stock. The warrants have an exercise price of $2.29 per share and are exercis
